This morning Senseonics (NYSE: SENS) announced they have received a date from the FDA for a panel review of their Eversense implantable CGM. Per a company issued press release;
“Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices Panel is scheduled to review the premarket approval application (PMA) for Eversense on Thursday, March 29, 2018.”
So once again the diabetes device world . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.